Safety and Efficacy Trial of Escalation of Plerixafor for Mobilization of CD34+ Hematopoietic Progenitor Cells and Evaluation of Globin Gene Transfer in Patients With Sickle Cell Disease

Study Summary

The purpose of this research study is to test the safety and efficacy of a drug called Plerixafor. Plerixafor is approved by the US FDA for use in increasing blood stem cell counts before collection in cancer patients. It is not yet approved for patients with sickle cell disease. The investigators want to find out if Plerixafor can be used to increase cell counts in patients with sickle cell disease.

Interventions

Study Locations

Facility	City	State	Country
Memorial Sloan Kettering Cancer Center	New York	New York	United States
Weill Cornell Medical College	New York	New York	United States

Official Trial Information

View on ClinicalTrials.gov